Net Income (Loss) Attributable to Parent in USD of Checkpoint Therapeutics, Inc. from Q4 2014 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Checkpoint Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q4 2014 to Q1 2025.
  • Checkpoint Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Mar 2025 was -$11.2M, a 2.44% decline year-over-year.
  • Checkpoint Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Mar 2025 was -$56.5M, a 8.01% decline year-over-year.
  • Checkpoint Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$56.2M, a 8.47% decline from 2023.
  • Checkpoint Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$51.8M, a 17.2% increase from 2022.
  • Checkpoint Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$62.6M, a 10.5% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Checkpoint Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$56.5M -$11.2M -$267K -2.44% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025
Q4 2024 -$56.2M -$28.9M -$9.77M -51.1% 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025
Q3 2024 -$46.5M -$9.73M -$4M -69.9% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 -$42.5M -$6.67M +$9.85M +59.6% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2024
Q1 2024 -$52.3M -$10.9M -$471K -4.5% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025
Q4 2023 -$51.8M -$19.1M +$1.89M +9.01% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2025
Q3 2023 -$53.7M -$5.72M +$4.89M +46.1% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$58.6M -$16.5M -$2.38M -16.8% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024
Q1 2023 -$56.3M -$10.5M +$6.37M +37.8% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024
Q4 2022 -$62.6M -$21M +$8.73M +29.4% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024
Q3 2022 -$71.4M -$10.6M +$653K +5.8% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$72M -$14.1M -$5M -54.7% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$67M -$16.8M -$10.3M -159% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$56.7M -$29.8M -$19.5M -191% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$37.1M -$11.3M -$6.34M -128% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$30.8M -$9.14M -$4.5M -96.9% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022
Q1 2021 -$26.3M -$6.51M -$3.22M -98.3% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 -$23.1M -$10.2M -$1.4M -15.9% 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022
Q3 2020 -$21.7M -$4.93M +$276K +5.3% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 -$22M -$4.65M +$147K +3.07% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021
Q1 2020 -$22.1M -$3.28M +$2.61M +44.3% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021
Q4 2019 -$24.7M -$8.83M +$2.79M +24% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2021
Q3 2019 -$27.5M -$5.21M +$4.14M +44.3% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020
Q2 2019 -$31.6M -$4.79M +$1.85M +27.8% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 -$33.5M -$5.89M +$2.88M +32.8% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 -$36.4M -$11.6M -$5.7M -96.3% 01 Oct 2018 31 Dec 2018 10-K 18 Mar 2019
Q3 2018 -$30.7M -$9.34M -$3.42M -57.6% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$27.3M -$6.64M -$191K -2.96% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 -$27.1M -$8.77M -$4.38M -100% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019
Q4 2017 -$22.7M -$5.92M +$2.41M +28.9% 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019
Q3 2017 -$25.1M -$5.93M -$800K -15.6% 01 Jul 2017 30 Sep 2017 10-K 18 Mar 2019
Q2 2017 -$24.3M -$6.45M -$1.04M -19.3% 01 Apr 2017 30 Jun 2017 10-K 18 Mar 2019
Q1 2017 -$23.2M -$4.38M -$778K -21.6% 01 Jan 2017 31 Mar 2017 10-K 18 Mar 2019
Q4 2016 -$22.5M -$8.32M -$272K -3.38% 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 -$22.2M -$5.13M -$1.38M -36.8% 01 Jul 2016 30 Sep 2016 10-K 16 Mar 2018
Q2 2016 -$20.8M -$5.41M -$4.93M -1038% 01 Apr 2016 30 Jun 2016 10-K 16 Mar 2018
Q1 2016 -$15.9M -$3.61M -$1.99M -123% 01 Jan 2016 31 Mar 2016 10-K 16 Mar 2018
Q4 2015 -$13.9M -$8.05M -$8.05M 01 Oct 2015 31 Dec 2015 10-K 21 Mar 2017
Q3 2015 -$5.84M -$3.75M 01 Jul 2015 30 Sep 2015 10-K 21 Mar 2017
Q2 2015 -$475K 01 Apr 2015 30 Jun 2015 10-K 21 Mar 2017
Q1 2015 -$1.62M 01 Jan 2015 31 Mar 2015 10-K 21 Mar 2017
Q4 2014 $0 10 Nov 2014 31 Dec 2014 10-K 21 Mar 2017

Checkpoint Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$56.2M -$4.39M -8.47% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025
2023 -$51.8M +$10.8M +17.2% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025
2022 -$62.6M -$5.95M -10.5% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024
2021 -$56.7M -$33.6M -146% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$23.1M +$1.63M +6.61% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022
2019 -$24.7M +$11.7M +32% 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021
2018 -$36.4M -$13.7M -60.4% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020
2017 -$22.7M -$216K -0.96% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019
2016 -$22.5M -$8.57M -61.7% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2018
2015 -$13.9M 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.